SNFGE SNFGE
 
Thématique :
- Endoscopie/Imagerie
- Cancers autres (hors CCR et CHC)
- Œsophage/Estomac
Originalité :
Réexamen
Solidité :
Très solide
Doit faire évoluer notre pratique :
Immédiatement
 
 
Nom du veilleur :
Docteur Patrice PIENKOWSKI
Coup de coeur :
 
 
Endoscopy
  2015/09  
 
  2015 Sep;47(9):829-54  
  doi: 10.1055/s-0034-1392882  
 
  Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline  
 
  Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, Repici A, Vieth M, De Ceglie A,Amato A, Berr F, Bhandari P, Bialek A, Conio M, Haringsma J, Langner C,Meisner S, Messmann H, Morino M, Neuhaus H, Piessevaux H, Rugge M,Saunders BP, Robaszkiewicz M, Seewald S, Kashin S, Dumonceau JM, Hassan C, Deprez PH  
  http://www.ncbi.nlm.nih.gov/pubmed/26317585  
 
 

This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system 1 2 was adopted to define the strength of recommendations and the quality of evidence. Main recommendations 1 ESGE recommends endoscopic en bloc resection for superficial esophageal squamous cell cancers (SCCs), excluding those with obvious submucosal involvement (strong recommendation, moderate quality evidence). Endoscopic mucosal resection (EMR) may be considered in such lesions when they are smaller than 10 mm if en bloc resection can be assured. However, ESGE recommends endoscopic submucosal dissection (ESD) as the first option, mainly to provide an en bloc resection with accurate pathology staging and to avoid missing important histological features (strong recommendation, moderate quality evidence). 2 ESGE recommends endoscopic resection with a curative intent for visible lesions in Barrett's esophagus (strong recommendation, moderate quality evidence). ESD has not been shown to be superior to EMR for excision of mucosal cancer, and for that reason EMR should be preferred. ESD may be considered in selected cases, such as lesions larger than 15 mm, poorly lifting tumors, and lesions at risk for submucosal invasion (strong recommendation, moderate quality evidence). 3 ESGE recommends endoscopic resection for the treatment of gastric superficial neoplastic lesions that possess a very low risk of lymph node metastasis (strong recommendation, high quality evidence). EMR is an acceptable option for lesions smaller than 10 - 15 mm with a very low probability of advanced histology (Paris 0-IIa). However, ESGE recommends ESD as treatment of choice for most gastric superficial neoplastic lesions (strong recommendation, moderate quality evidence). 4 ESGE states that the majority of colonic and rectal superficial lesions can be effectively removed in a curative way by standard polypectomy and/or by EMR (strong recommendation, moderate quality evidence). ESD can be considered for removal of colonic and rectal lesions with high suspicion of limited submucosal invasion that is based on two main criteria of depressed morphology and irregular or nongranular surface pattern, particularly if the lesions are larger than 20 mm; or ESD can be considered for colorectal lesions that otherwise cannot be optimally and radically removed by snare-based techniques (strong recommendation, moderate quality evidence).

 
Question posée
 
Synthèse des recommandations européennes en matière de dissection sous-muqueuse.
 
Question posée
 
-Résection monobloc de cancer épidermoïde superficiel de l’œsophage de moins de 10 mm sans critère manifeste d’extension sous-muqueuse (préférence à la dissection sous-muqueuse) -Lésions macroscopique de Barret (dissection en cas de lésion de plus de 15 mm) -Lésions néoplasiques superficielles de l’estomac à faible risque d’extension ganglionnaire (EMR pour les lésions de moins de 15 mm, Paris 0-IIa, ESD pour les autres) -Lésions superficielles du côlon et du rectum (ESD si suspicion d’invasion sous-muqueuse ou si taille > 20 mm).
 
Commentaires

A lire dans le détail par tous ceux qui s’intéressent à ces aspects de l’endoscopie thérapeutique.

 
www.snfge.org